Abstract:Targeting solid tumors and their metastases continue to be viewed as an essential aspect of therapeutic success to achieve long-term tumor control. Targeted therapy is a promising approach in this regard and the utilization of human proteins assures the potential for long-term therapy without immunological restrictions. VEGF 121 is a naturally-occurring splice variant that binds to both VEGFR-1 and VEGFR-2 receptors over-expressed on the endothelium of tumor vasculature but not normal vasculature. The serine protease granzyme B (GrB) is capable of inducing intense cellular apoptosis through both caspase-dependent and caspase-independent multiple-cascade mechanisms. We expressed pro-GrB/VEGF 121 in HEK293T cells and harvested the fusion protein under serum-free conditions. The purified protein expressed as a homodimer and Western blotting confirmed incorporation of both VEGF 121 and GrB components into the construct. Comparison of GrB/VEGF 121 with its expected molecular weight by SDS-PAGE suggests minimal (1-2 kDa) glycosylation. The enzymatic activity of GrB in GrB/VEGF 121 was comparable to that of human GrB. The cytotoxicity of GrB/VEGF 121 confirmed specific targeting and internalization into PAE/hVEGFR-2 (IC 50 ∼ 10 nM), but not PAE/hVEGFR-1 cells (IC 50 > 300 nM). GrB/VEGF 121 induced apoptosis in PAE/VEGFR-2, but not PAE/VEGFR-1 cells, as determined by Annexin V staining. The targeting efficacy of GrB/VEGF 121 against a panel of cells expressing a range of VEGFR receptor levels is under study. Studies investigating GrB/VEGF 121 signaling events and in vivo efficacy against various tumor models are currently ongoing and will be presented. Research conducted, in part, by the Clayton Foundation for Research. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3874. doi:1538-7445.AM2012-3874

Establishment of Hela cell line inducibly expressing human active granzyme B

Expression of Human Granzyme B Gene in HeLa Cells

Apoptosis in HeLa cells caused by the inducible expresion of human granzyme B fusinon protein gene

Apoptosis in HeLa cells caused by the inducible expression of human granzyme B fusion protein gene

Cloning,Purification and Prokaryotic Expression of Human Granzyme B Gene

Ectopic Expression of Active Granzyme B Gene Leads to Multinuclear Giant Cels

Expression of Two Chimeric Human Granzyme B Genes and Their Killing Activities of Tumor Cells

[Construction and Expression of Recombinant Antibody/granzyme B Containing Truncated Translocating Peptide].

The effect of human granzyme B -PE domain IIfusion protein on transfected HeLa cells

The Effect of Human Granzyme B -PE Domain Ⅱfusion Protein on Transfected HeLa Cells

[Growth Inhibitory Effects of Recombinant Granzyme B Containing Different N-terminal Translocating Peptides].

Establishment and Identification of HGPRT Deficient Hela Cell Line

Secreted Antibody/granzyme B Fusion Protein Stimulates Selective Killing of HER2-overexpressing Tumor Cells.

The Establishment of Stable Expression of GRIM-19 in Hela Cell Line and Its Inhibitive Effect on STAT3 Expression

Improved Purification of Human Granzyme A/B and Granulysin Using a Mammalian Expression System

Expression and Purification of Human Granzyme B Fusion Protein to Induce Targeted Apoptosis in PSMA Positive Prostate Cancer Cells

Human Plasma Cells Express Granzyme B

Structural basis for proteolytic specificity of the human apoptosis-inducing granzyme M.

Construction of enhanced green fluorescent (EGFP) tagged Hela cell subline

[Construction, Expression and Cell Growth Inhibition of Translocating Peptide/granzyme B Fusion Protein Gene].

A Novel Human Fusion Protein Composed Of The Serine Protease Granzyme B And Vegf(121) To Target The Vasculature Of Solid Tumors